Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-26T10:05:40.806Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk of Hepatitis C After Immunoadsorption

Published online by Cambridge University Press:  02 January 2015

Rolf Kaiser ,
Oliver Geulen ,
Bertfried Matz ,
Hans H. Brackmann ,
Ulrich Spengler ,
Michael H. Kramer ,
Martin Exner ,
Wilhelm Nettekoven ,
You-Dschun Ko  and
Heike Zeitler
...Show all authors
Rolf Kaiser
Affiliation:
Institute of Medical Microbiology and Immunology, University of Bonn, Bonn, Germany
Oliver Geulen
Affiliation:
Institute of Medical Microbiology and Immunology, University of Bonn, Bonn, Germany
Bertfried Matz
Affiliation:
Institute of Medical Microbiology and Immunology, University of Bonn, Bonn, Germany
Hans H. Brackmann
Affiliation:
Institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany
Ulrich Spengler
Affiliation:
Department of Internal Medicine, University of Bonn, Bonn, Germany
Michael H. Kramer*
Affiliation:
Institute of Hygiene, University of Bonn, Bonn, Germany
Martin Exner
Affiliation:
Institute of Hygiene, University of Bonn, Bonn, Germany
Wilhelm Nettekoven
Affiliation:
Medical Policlinic, University of Bonn, Bonn, Germany
You-Dschun Ko
Affiliation:
Medical Policlinic, University of Bonn, Bonn, Germany
Heike Zeitler
Affiliation:
Medical Policlinic, University of Bonn, Bonn, Germany
Hans Vetter
Affiliation:
Medical Policlinic, University of Bonn, Bonn, Germany
*
Center for Infectious Disease Epidemiology, Robert Koch-Institute, Stresemannstr. 90, 10963 Berlin, Germany
Get access Rights & Permissions [Opens in a new window]

Abstract

An episode of acute hepatitis in a patient with hemophilia during immunoadsorption therapy initially was misinterpreted as a reactivated hepatitis C virus (HCV) infection, but ultimately was shown to be an exogenous reinfection during cohort treatment with another HCV-positive patient. This incident illustrates that policies for the prevention of nosocomial transmission of blood-borne pathogens, especially in cohort treatment units, may need to be reassessed.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 23 , Issue 6 , June 2002 , pp. 342 - 343
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Brackmann, HH, Oldenburg, J, Schwaab, R. Immune tolerance for the treatment of factor VIII inhibitor: twenty years ‘Bonn Protocol’. Vox Sang 1996;70(suppl 1):30–35.Google ScholarPubMed
2.Knöbl, P, Derfler, K, Korninger, L, et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995;74:1035–1038.Google Scholar
3.Weiner, AJ, Geysen, HM, Christopherson, C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992;89:3468–3472.Google Scholar
4.Stoesser, G, Baker, W, van den Broek, A, et al. The EMBL Nucleotide Sequence Database. Nucleic Acids Res 2001;29:17–21.Google Scholar
5.Golder, M, Chan, CLH, O'Shea, S, Corbett, K, Chrystie, IL, French, G. Potential risk of cross-infection during peripheral-venous access by contamination of tourniquets. Lancet 2000;355:44.Google Scholar
6.Lai, ME, Mazzoleni, AP, Argiolu, F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994;343:388–390.CrossRefGoogle ScholarPubMed